A Phase 1b Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility

Trial Profile

A Phase 1b Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Feb 2018

At a glance

  • Drugs Reldesemtiv (Primary)
  • Indications Muscular atrophy
  • Focus Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 15 Feb 2018 According to a Cytokinetics media release, results are anticipated in 2H 2018.
    • 15 Feb 2018 According to a Cytokinetics media release, this trial has enrolled over 20 subjects towards the objective of 60 subjects.
    • 30 Nov 2017 According to a Cytokinetics media release, the results from this trial is anticipated in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top